These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28250535)

  • 21. Prudent use and regulatory guidelines for veterinary antibiotics-politics or science?
    Silley P; Stephan B
    J Appl Microbiol; 2017 Dec; 123(6):1373-1380. PubMed ID: 28779537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Innovation of novel antibiotics: an economic perspective.
    McKellar MR; Fendrick AM
    Clin Infect Dis; 2014 Oct; 59 Suppl 3():S104-7. PubMed ID: 25261536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
    Hodgkin D; Horgan CM; Creedon TB; Merrick EL; Stewart MT
    J Ment Health Policy Econ; 2015 Dec; 18(4):165-73. PubMed ID: 26729008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging trends in antibiotic use in US hospitals: quality, quantification and stewardship.
    Jacob JT; Gaynes RP
    Expert Rev Anti Infect Ther; 2010 Aug; 8(8):893-902. PubMed ID: 20695745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [EU law on marketing authorization of medicines. History, current state of development and perspectives].
    Nettesheim M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):705-12. PubMed ID: 18560781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
    Towse A; Hoyle CK; Goodall J; Hirsch M; Mestre-Ferrandiz J; Rex JH
    Health Policy; 2017 Oct; 121(10):1025-1030. PubMed ID: 28888660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The future of antibiotics.
    Spellberg B
    Crit Care; 2014 Jun; 18(3):228. PubMed ID: 25043962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of various antimicrobial stewardship programs on antimicrobial usage and resistance among common gram-negative bacilli causing health care-associated infections: A multicenter comparison.
    Lai CC; Shi ZY; Chen YH; Wang FD
    J Microbiol Immunol Infect; 2016 Feb; 49(1):74-82. PubMed ID: 26586483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of systemic antibiotics in a Norwegian nursing home].
    Tobiassen T; Berild D; Hjortdahl P
    Tidsskr Nor Laegeforen; 2002 Oct; 122(24):2376-8. PubMed ID: 12448254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Procedure for the marketing authorization of an antibacterial agent].
    López Navas A; García-Escribano Ráez N; Flores Juberías Á; Suárez Gea ML
    Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):529-32. PubMed ID: 25124488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: findings and implications.
    Fürst J; Čižman M; Mrak J; Kos D; Campbell S; Coenen S; Gustafsson LL; Fürst L; Godman B
    Expert Rev Anti Infect Ther; 2015 Feb; 13(2):279-89. PubMed ID: 25495147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to antibiotics: are we in the post-antibiotic era?
    Alanis AJ
    Arch Med Res; 2005; 36(6):697-705. PubMed ID: 16216651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can antibiotic use be both just and sustainable... or only more or less so?
    Millar M
    J Med Ethics; 2011 Mar; 37(3):153-7. PubMed ID: 21059636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can antibiotic prescriptions in respiratory tract infections be improved? A cluster-randomized educational intervention in general practice--the Prescription Peer Academic Detailing (Rx-PAD) Study [NCT00272155].
    Gjelstad S; Fetveit A; Straand J; Dalen I; Rognstad S; Lindbaek M
    BMC Health Serv Res; 2006 Jun; 6():75. PubMed ID: 16776824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.
    Rex JH; Outterson K
    Lancet Infect Dis; 2016 Apr; 16(4):500-5. PubMed ID: 27036356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Marketing authorization for pharmaceuticals: the necessity of European collaboration].
    Seitz R; Enzmann H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):703-4. PubMed ID: 18592336
    [No Abstract]   [Full Text] [Related]  

  • 37. Valuing reduced antibiotic use for pediatric acute otitis media.
    Meropol SB
    Pediatrics; 2008 Apr; 121(4):669-73. PubMed ID: 18381529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of prospective and continuous parenteral antibiotic control: experience at the Palo Alto Veterans Affairs Medical Center from 1987 to 1989.
    Coleman RW; Rodondi LC; Kaubisch S; Granzella NB; O'Hanley PD
    Am J Med; 1991 Apr; 90(4):439-44. PubMed ID: 1901446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The additional costs of antibiotics and re-consultations for antibiotic-resistant Escherichia coli urinary tract infections managed in general practice.
    Alam MF; Cohen D; Butler C; Dunstan F; Roberts Z; Hillier S; Palmer S
    Int J Antimicrob Agents; 2009 Mar; 33(3):255-7. PubMed ID: 19091516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence, consequences, and solutions.
    Maki DG; Safdar N; Ebert SC
    Pharmacotherapy; 2007 Oct; 27(10 Pt 2):121S-125S. PubMed ID: 17896904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.